BR9609178A - Processo para reproduzir in vitro a atividade de rna-polimerase dependente de rna ou a atividade terminal-nucleotidil-transferase codificadas pelo vírus da hepatite c composição de material e uso de composições de material - Google Patents

Processo para reproduzir in vitro a atividade de rna-polimerase dependente de rna ou a atividade terminal-nucleotidil-transferase codificadas pelo vírus da hepatite c composição de material e uso de composições de material

Info

Publication number
BR9609178A
BR9609178A BR9609178A BR9609178A BR9609178A BR 9609178 A BR9609178 A BR 9609178A BR 9609178 A BR9609178 A BR 9609178A BR 9609178 A BR9609178 A BR 9609178A BR 9609178 A BR9609178 A BR 9609178A
Authority
BR
Brazil
Prior art keywords
hepatitis
rna
rna polymerase
virus
material composition
Prior art date
Application number
BR9609178A
Other languages
English (en)
Inventor
Licia Tomei
Raffaele De Francesco
Sven-Erik Behrens
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11403393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9609178(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of BR9609178A publication Critical patent/BR9609178A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9609178A 1995-05-25 1996-05-24 Processo para reproduzir in vitro a atividade de rna-polimerase dependente de rna ou a atividade terminal-nucleotidil-transferase codificadas pelo vírus da hepatite c composição de material e uso de composições de material BR9609178A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95RM000343A IT1278077B1 (it) 1995-05-25 1995-05-25 Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
PCT/IT1996/000106 WO1996037619A1 (en) 1995-05-25 1996-05-24 Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv)

Publications (1)

Publication Number Publication Date
BR9609178A true BR9609178A (pt) 1999-05-04

Family

ID=11403393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609178A BR9609178A (pt) 1995-05-25 1996-05-24 Processo para reproduzir in vitro a atividade de rna-polimerase dependente de rna ou a atividade terminal-nucleotidil-transferase codificadas pelo vírus da hepatite c composição de material e uso de composições de material

Country Status (13)

Country Link
US (2) US6383768B1 (pt)
EP (1) EP0842276B1 (pt)
JP (1) JP3187432B2 (pt)
AT (1) ATE258227T1 (pt)
AU (1) AU708431B2 (pt)
BR (1) BR9609178A (pt)
CA (1) CA2220873C (pt)
DE (1) DE69631375T2 (pt)
DK (1) DK0842276T3 (pt)
ES (1) ES2211956T3 (pt)
IT (1) IT1278077B1 (pt)
PT (1) PT842276E (pt)
WO (1) WO1996037619A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
AU719122B2 (en) * 1995-09-27 2000-05-04 Emory University Recombinant hepatitis C virus RNA replicase
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase
WO1999029843A1 (en) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds
JP2002510509A (ja) * 1998-04-02 2002-04-09 バイロファーマ・インコーポレイテッド Ｃ型肝炎ウイルスｎｓ５ｂ組成物およびその使用方法
AU4393399A (en) * 1998-06-24 2000-01-10 Chugai Seiyaku Kabushiki Kaisha Hcv-derived rna polymerase gene
AU2181800A (en) * 1998-12-10 2000-06-26 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
US6297005B1 (en) 1999-05-04 2001-10-02 Schering Corporation De novo priming activity of hepatitis C virus replicase
JP2003514562A (ja) * 1999-11-23 2003-04-22 バイロファーマ・インコーポレイテッド ポリメラーゼ組成物およびその使用方法
AU764095B2 (en) * 2000-04-07 2003-08-07 Shionogi & Co., Ltd. Preincubation assay method
KR20020010241A (ko) * 2000-07-28 2002-02-04 허영섭 Ｃ형 간염 바이러스 ｒｎａ-의존성 ｒｎａ 중합효소의대량 발현 기구 및 이로부터 발현된 융합단백질을 이용한효소활성 분석방법
CA2434845C (en) 2001-01-23 2013-11-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus replicons and replicon enhanced cells
CN1880457B (zh) 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
ATE467680T1 (de) 2001-10-11 2010-05-15 Merck Sharp & Dohme Hepatitis-c-virus-impfstoff
CA2481171A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
US20040142322A1 (en) * 2002-10-07 2004-07-22 Schering Corporation Continuous non-radioactive polymerase assay
AU2003304040A1 (en) * 2002-10-08 2004-11-04 Viropharma Incorporated Anthranilic acid derivatives useful in treating infection with hepatitis c virus
EP1604020B1 (en) 2003-02-13 2009-12-16 Merck & Co., Inc. Method to confer cell culture replication activity to different hepatitis c virus isolates
WO2005047463A2 (en) 2003-11-05 2005-05-26 Merck & Co., Inc. Hcv replicons containing ns5b from genotype 2b
WO2005070957A1 (en) 2004-01-09 2005-08-04 Merck & Co., Inc. Hcv rna-dependent rna polymerase
US7985541B2 (en) * 2004-03-24 2011-07-26 Achillion Pharmaceuticals, Inc. Quantitative assay for detection of newly synthesized RNA in a cell-free system and identification of RNA synthesis inhibitors
EP1807397A2 (en) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetracyclic indole derivatives as antiviral agents
CA2604442A1 (en) * 2005-04-11 2006-10-19 Mingjun Huang Pharmaceutical compositions for and methods of inhibiting hcv replication
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
WO2007145894A2 (en) 2006-06-08 2007-12-21 Merck & Co., Inc. A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
BRPI0720625A2 (pt) 2006-12-22 2014-03-25 Schering Corp Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
AU2007339386B8 (en) 2006-12-22 2013-12-05 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
ATE543808T1 (de) 2006-12-22 2012-02-15 Schering Corp 5,6-ring-annelierte indolderivate und ihre verwendung
EP2481807A3 (en) 2007-03-09 2013-04-03 Merck Sharp & Dohme Corp. In vivo HCV resistance to anti-viral inhibitors
WO2009010785A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
CN101842353A (zh) 2007-08-29 2010-09-22 先灵公司 用于治疗病毒感染的2,3-取代的吲哚衍生物
CA2697500A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
EP2408761B1 (en) 2007-08-29 2014-01-01 Merck Sharp & Dohme Corp. Substituted indole derivatives and methods of use thereof
CA2705587A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
CA2705586A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
AR072088A1 (es) 2008-06-13 2010-08-04 Schering Corp Derivados de indol triciclicos y sus metodos de uso
EP2166016A1 (en) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidate Derivatives of Nucleosides
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0906026D0 (en) 2009-04-07 2009-05-20 Angeletti P Ist Richerche Bio Therapeutic compounds
BR112012007122A2 (pt) 2009-09-29 2016-07-12 Janssen Products Lp derivados de fosforamidatos de nucleosídeos
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652941B2 (en) * 1990-06-25 1994-09-15 Research Foundation For Microbial Diseases Of Osaka University, The Non-A, Non-B hepatitis virus particles
EP0464287A1 (en) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, non-B hepatitis virus genomic cDNA and antigen polypeptide
US5360714A (en) * 1992-08-28 1994-11-01 Fox Chase Cancer Center Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
AU719122B2 (en) 1995-09-27 2000-05-04 Emory University Recombinant hepatitis C virus RNA replicase

Also Published As

Publication number Publication date
DK0842276T3 (da) 2004-05-03
PT842276E (pt) 2004-05-31
ATE258227T1 (de) 2004-02-15
US7399605B2 (en) 2008-07-15
IT1278077B1 (it) 1997-11-17
JP3187432B2 (ja) 2001-07-11
CA2220873C (en) 2000-10-24
DE69631375D1 (de) 2004-02-26
US6383768B1 (en) 2002-05-07
JPH10507370A (ja) 1998-07-21
AU708431B2 (en) 1999-08-05
EP0842276A1 (en) 1998-05-20
CA2220873A1 (en) 1996-11-28
AU5909896A (en) 1996-12-11
DE69631375T2 (de) 2004-11-04
US20020164722A1 (en) 2002-11-07
ES2211956T3 (es) 2004-07-16
ITRM950343A1 (it) 1996-11-25
EP0842276B1 (en) 2004-01-21
ITRM950343A0 (it) 1995-05-25
WO1996037619A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
BR9609178A (pt) Processo para reproduzir in vitro a atividade de rna-polimerase dependente de rna ou a atividade terminal-nucleotidil-transferase codificadas pelo vírus da hepatite c composição de material e uso de composições de material
DE69324678D1 (de) Verfahren zur typisierung von hcv-isolaten
DK0770679T4 (da) HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
FI955224A (fi) Hepatiitti-C-virustyypit 4,5 ja 6
EA199900388A1 (ru) Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc)
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
GB1531558A (en) Compositions having affinity for hepatitis virus and method for hepatitis virus removal
EA200300819A1 (ru) Производные нуклеозидов в качестве ингибиторов рнк-зависимой рнк вирусной полимеразы
ATE244729T1 (de) Verfahren zur identifizierung von wirkstoffen gegen hcv durch verwendung von strukturkoordinaten der hepatitis-c-virus- protease
WO1997012043A3 (en) Hcv ns3 protein fragments having helicase activity and improved solubility
HUP0203305A2 (hu) Fertőző klónok
ATE281647T1 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
DE69333914D1 (de) Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
NZ518999A (en) Vaccine compositions
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
BRPI0414157A (pt) polipeptìdeo isolado, ácido nucleico isolado, método para inibir a infecção por vìrus da sìndrome da mancha branca de um crustáceo, e, alimento para um crustáceo
DE69334328D1 (de) Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
EP1331267A3 (en) Oligonucleotides specific for hepatitis C virus
WO2002088338A3 (fr) Procede de replication du virus de l'hepatite c
KR910016347A (ko) C형 간염 바이러스에 대한 초면역 글로블린 및 이의 제조방법
KR940021732A (ko) C형 간염 바이러스의 비구조 4 부분 단백질의 발현
BR0204599A (pt) Sequências de proteìna de núcleo de hcv
WO2003014728A1 (fr) Medicaments contre l'hepatite c
KR940021733A (ko) C형 간염 바이러스의 비구조 5-1.2 단백질의 제조방법

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]